Literature DB >> 28652870

Global implementation of advanced urological care: Policy implementation research.

Lynn Stothers1, Andrew Macnab2.   

Abstract

INTRODUCTION: In high-resource countries, modern treatments for urological diseases have led to significant reductions in mortality and morbidity; however, the benefits of modern treatment have yet to reach the majority of people worldwide. As attention is focused on improving urological care in the global community, policy and implementation research (PIR) offers a platform for effective organization and engagement.
METHODS: We have compiled a photo essay to illustrate the fundamental components of PIR.
RESULTS: There are four central components to the conduct of PIR. These are: 1) understanding the unique characteristics of the environment; 2) studying the implementation processes that fit within the environment; 3) testing innovative and novel ways to implement; and 4) programmatic implementation and scale-up.
CONCLUSIONS: PIR is a process that will help to identify, quantify, prioritize, and implement translation of modern methods of care to meet specific global needs.

Entities:  

Year:  2017        PMID: 28652870      PMCID: PMC5472457          DOI: 10.5489/cuaj.4117

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  8 in total

Review 1.  Community health workers in low-, middle-, and high-income countries: an overview of their history, recent evolution, and current effectiveness.

Authors:  Henry B Perry; Rose Zulliger; Michael M Rogers
Journal:  Annu Rev Public Health       Date:  2014-01-02       Impact factor: 21.981

2.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

3.  Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.

Authors:  Debra E Irwin; Zoe S Kopp; Barnabie Agatep; Ian Milsom; Paul Abrams
Journal:  BJU Int       Date:  2011-01-13       Impact factor: 5.588

4.  An assessment of the comprehension of the American Urological Association Symptom Index.

Authors:  S A MacDiarmid; T C Goodson; T M Holmes; P R Martin; R B Doyle
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

5.  Prospective comparison of a new visual prostate symptom score versus the international prostate symptom score in men with lower urinary tract symptoms.

Authors:  Chris L E van der Walt; Chris F Heyns; Adam E Groeneveld; Rachel S Edlin; Stephan P J van Vuuren
Journal:  Urology       Date:  2011-05-07       Impact factor: 2.649

6.  Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph.

Authors:  P Boyle; P Maisonneuve; A Steg
Journal:  J Urol       Date:  1996-01       Impact factor: 7.450

7.  Associations between the severity of obstructive lower urinary tract symptoms and care-seeking behavior in rural Africa: A cross-sectional survey from Uganda.

Authors:  Lynn Stothers; Andrew J Macnab; Francis Bajunirwe; Sharif Mutabazi; Jonathan Berkowitz
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

8.  Transforming Global Health by Improving the Science of Scale-Up.

Authors:  Margaret E Kruk; Gavin Yamey; Sonia Y Angell; Alix Beith; Daniel Cotlear; Frederico Guanais; Lisa Jacobs; Helen Saxenian; Cesar Victora; Eric Goosby
Journal:  PLoS Biol       Date:  2016-03-02       Impact factor: 8.029

  8 in total
  1 in total

1.  Prevalence estimates for lower urinary tract symptom severity among men in Uganda and sub-Saharan Africa based on regional prevalence data.

Authors:  Francis Bajunirwe; Lynn Stothers; Jonathan Berkowitz; Andrew J Macnab
Journal:  Can Urol Assoc J       Date:  2018-06-08       Impact factor: 1.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.